Compounding these risks is the fact that long-term effects remain largely unknown, as millions of people are still in the early stages of taking these medications
[4] As a result, GLP-1 agonists are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or those with multiple endocrine neoplasia syndrome type 2 (MEN 2), a genetic disorder that increases the risk of certain types of tumors
The distinction between research peptides and pharmaceutical-grade compounds becomes relevant here, as semaglutide has extensive FDA-approved clinical trial data behind it while sermorelin operates primarily in the compounding pharmacy space for adult applications
(Other brands have wisely piggybacked off of Pinnells research
Women considering affordable tirzepatide options may find that the switch addresses both cost and sexual side effect concerns
The ghrelin receptor pathway can boost GH release even when GHRH receptors are already started, and the two pathways show combined interactions